Antibodies
30 March 2010
Lpath Completes Successful Phase I Study With ASONEP in Cancer Patients and Achieves $2 Million Merck KGaA Milestone29 March 2010
Erbitux Granted extended Use in Japan for First-Line-Treatment for mCRC-Patients with KRAS wild-type Tumors26 March 2010
ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERY22 March 2010
Zenyaku Kogyo Obtains Exclusive License in Japan to Theraclone’s Influenza Monoclonal Antibody Program19 March 2010
Anti-Cancer Agents, Herceptin and Xeloda17 March 2010
CytoDyn Begins Full Humanization of Cytolin17 March 2010
HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN NON-SMALL CELL LUNG CANCER16 March 2010
4-Antibody Announces a Long-Term Collaboration With Boehringer Ingelheim for Therapeutic Antibodies16 March 2010
Single Short Course of Tolerx’s Otelixizumab Provides Prolonged Preservation of Beta Cell Function15 March 2010
Innate Immune, Inc. Enters into a License and Commercialization Agreement with Cephalon Australia Pty Ltd12 March 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer11 March 2010
BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies8 March 2010
Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients4 March 2010
CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy1 March 2010
arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodiesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports